1.97
+0.02(+1.03%)
Currency In USD
| Previous Close | 1.95 |
| Open | 1.97 |
| Day High | 2.01 |
| Day Low | 1.94 |
| 52-Week High | 3.8 |
| 52-Week Low | 1.26 |
| Volume | 49,778 |
| Average Volume | 167,170 |
| Market Cap | 54.19M |
| PE | -2.35 |
| EPS | -0.84 |
| Moving Average 50 Days | 2.1 |
| Moving Average 200 Days | 2 |
| Change | 0.02 |
If you invested $1000 in Immix Biopharma, Inc. (IMMX) since IPO date, it would be worth $536.78 as of February 05, 2025 at a share price of $1.97. Whereas If you bought $1000 worth of Immix Biopharma, Inc. (IMMX) shares 3 years ago, it would be worth $410.42 as of February 05, 2025 at a share price of $1.97.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
GlobeNewswire Inc.
Jan 07, 2025 2:34 PM GMT
Successfully dosed 6 patients in safety run-in segment, now accelerating enrollmentPositive data from first four patients announced December 2024NXC-201 is the only one-time CAR-T therapy in development for AL AmyloidosisNext program update Q1 2025 A
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
GlobeNewswire Inc.
Dec 19, 2024 2:35 PM GMT
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis Immix Biopharma, Inc. (Nasdaq:IMMX) All four patie
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
GlobeNewswire Inc.
Dec 16, 2024 2:48 PM GMT
Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling clinical activity, rapid and deep complete responses in frail and resistant relapsed/refra